OXBOW Equities Corp.

OXBOW Equities Corp.

February 25, 2005 16:15 ET

Oxbow Announces Sale of its Mission Medical Ownership for C$16 Million


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: OXBOW EQUITIES CORP.

TSX SYMBOL: XBO

FEBRUARY 25, 2005 - 16:15 ET

Oxbow Announces Sale of its Mission Medical Ownership
for C$16 Million

MONTREAL, QUEBEC--(CCNMatthews - Feb. 25, 2005) - Not for Distribution
in the United States

Oxbow Equities Corp. ("Oxbow") (TSX:XBO) today announced the closing of
the previously disclosed transaction whereby Terumo Medical Corporation
("Terumo") is purchasing for a cash amount of US$18.0 million all 78% of
the shares of Mission Medical, Inc ("Mission") that it did not already
own.

The cash portion to Oxbow of the sale of its 54% Mission ownership to
Terumo amounts to approximately US$13.0 million (C$16.0 million),
resulting in a 28% gain (approximately C$3.4 million) over carrying
value as of September 30, 2004.

Oxbow currently has approximately C$18.4 million in cash ($0.24 per
share) from the combined proceeds of C$16.0 million from the sale of the
Corporation's ownership in Mission and the proceeds of C$2.35 million
from the private placement of Oxbow common shares which closed earlier
in the month. The total number of Oxbow common shares issued and
outstanding is 76,660,675.

Oxbow presently intends to distribute to its shareholders, probably
during 2005, the net proceeds of approximately $0.20 per share from the
sale of its interest in Mission to Terumo, once it is satisfied that the
ongoing capital needs of its other investee company, MonoGen, Inc., have
been met.

Oxbow President and CEO Andre Denis commented: "The sale of our
ownership in Mission provides a timely opportunity for Oxbow to realize
its investment in Mission in light of Mission's current stage of
development and challenges and opportunities going forward. By selling
its Mission shares to Terumo now, Oxbow recoups its invested capital,
realizes a 28% gain on its Mission investment and avoids having to
provide any of the additional funding that Mission requires to complete
the development of its products."

Oxbow (www.oxbowequities.com) is a publicly traded venture management
and venture capital corporation whose assets are substantially comprised
of a 47% ownership position in MonoGen, Inc. (www.monogen.com), a U.S.
private medical device company, and cash. Oxbow is an active investor in
MonoGen, providing strategic direction and management in addition to
capital.

The common shares of Oxbow are listed for trading on the Toronto Stock
Exchange under the trading symbol "XBO".

This news release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties and other factors that may cause
Oxbow's results to differ materially from expectations. These include
risks relating to market fluctuations, investee performance and other
risks. These forward-looking statements speak only as of the date
hereof. Oxbow disclaims any intent or obligation to update these
forward-looking statements.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Oxbow Equities Corp.
    Mr. Andre Denis
    President and Chief Executive Officer
    (514) 286-0999, ext. 224
    (514) 286-3777 (FAX)
    adenis@oxbowequities.com